AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 4013627 — intervention group
Group type: COMPARATOR
Intervention: Centrally acting analgesics alone
Number of subjects: 94
Study 31394525 — intervention group
Group type: EXPERIMENTAL
Intervention: Morning vaccination
Number of subjects: 26
Study 31394525 — intervention group
Group type: COMPARATOR
Intervention: Evening vaccination
Number of subjects: 26
Study 31394525 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (morning and evening)
Number of subjects: 26
Study 30185931 — intervention group
Group type: EXPERIMENTAL
Intervention: Thyroid hormone replacement treatment
Number of subjects: 1034
Study 30185931 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1034
Study 25611082 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity intermittent exercise
Number of subjects: 0
Study 25611082 — intervention group
Group type: COMPARATOR
Intervention: Moderate-intensity continuous exercise
Number of subjects: 0
Study 25190728 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy protein supplementation (n = 70)
Number of subjects: 140
Study 25190728 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 70)
Number of subjects: 140
Study 22872368 — intervention group
Group type: EXPERIMENTAL
Intervention: End-expiratory levels (EEL) with normal tidal volume
Number of subjects: 10
Study 22872368 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased tidal volume (V (T)) with maintained normal EEL (FRC)
Number of subjects: 10
Study 20130482 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai chi (TC)
Number of subjects: 35
Study 19022123 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP) administered into extraction sockets
Number of subjects: 12
Study 19022123 — intervention group
Group type: COMPARATOR
Intervention: Control group (no PRP treatment)
Number of subjects: 12
Study 16798622 — intervention group
Group type: EXPERIMENTAL
Intervention: subcutaneous recombinant interleukin-2 (rIL-2) plus antiretroviral therapy (ART)
Number of subjects: 4150
Study 16798622 — intervention group
Group type: COMPARATOR
Intervention: ART alone
Number of subjects: 4150
Study 14714359 — intervention group
Group type: EXPERIMENTAL
Intervention: Jiexiao Oral Liquid (JXOL)
Number of subjects: 160
Study 14714359 — intervention group
Group type: COMPARATOR
Intervention: Virazole (10-15 mg.kg-1.d-1)
Number of subjects: 160
Study 11084104 — intervention group
Group type: EXPERIMENTAL
Intervention: Single biphasic shock from right ventricle + left ventricle‐ ‐> superior vena cava+ + CAN+
Number of subjects: 51
Study 11084104 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual biphasic shock from right ventricle‐ ‐> superior vena cava+ + CAN+ followed by another 40% tilt biphasic shock from left ventricle‐ ‐> superior vena cava+ + CAN+
Number of subjects: 51
Study 11084104 — intervention group
Group type: COMPARATOR
Intervention: Standard ICD shock configuration (Control: right ventricle‐ ‐> superior vena cava+ + CAN+)
Number of subjects: 51
Study 9363044 — intervention group
Group type: EXPERIMENTAL
Intervention: Abecarnil (high dosage)
Number of subjects: 464
Study 9363044 — intervention group
Group type: EXPERIMENTAL
Intervention: Abecarnil (low dosage)
Number of subjects: 464
Study 9363044 — intervention group
Group type: EXPERIMENTAL
Intervention: Buspirone
Number of subjects: 464
Study 9363044 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 464
Study 1526085 — intervention group
Group type: EXPERIMENTAL
Intervention: Bendroflumethiazide (5 mg daily for 1 week)
Number of subjects: 32
Study 1526085 — intervention group
Group type: EXPERIMENTAL
Intervention: Transbuccal nitroglycerin (0.25 mg)
Number of subjects: 32
Study 1526085 — intervention group
Group type: COMPARATOR
Intervention: Unmedicated
Number of subjects: 32
Study 3532744 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk factors (serum cholesterol concentration, diastolic blood pressure, cigarette smoking)
Number of subjects: 325348
Study 3532744 — intervention group
Group type: EXPERIMENTAL
Intervention: Elimination of risk factors
Number of subjects: 325348
Study 30452706 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% rapeseed oil
Number of subjects: 1080
Study 30452706 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% rapeseed oil
Number of subjects: 1080
Study 30452706 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapeseed oil
Number of subjects: 1080
Study 30452706 — intervention group
Group type: EXPERIMENTAL
Intervention: MH rapeseed oil
Number of subjects: 1080
Study 30452706 — intervention group
Group type: EXPERIMENTAL
Intervention: Low erucic acid or 2% rapeseed oil
Number of subjects: 1080
Study 30452706 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1080
Study 29776960 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid (2.5 mg), vitamin B6 (50 mg), vitamin B12 (1 mg)
Number of subjects: 300
Study 29776960 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 300
Study 27083381 — intervention group
Group type: EXPERIMENTAL
Intervention: Miller blade
Number of subjects: 30
Study 27083381 — intervention group
Group type: COMPARATOR
Intervention: GlideScope
Number of subjects: 30
Study 27083381 — intervention group
Group type: COMPARATOR
Intervention: Truview PCD
Number of subjects: 30
Study 24939906 — intervention group
Group type: EXPERIMENTAL
Intervention: RV1 at 6, 10, and 14 weeks
Number of subjects: 630
Study 24939906 — intervention group
Group type: COMPARATOR
Intervention: RV1 at 6 and 10 weeks
Number of subjects: 630
Study 24939906 — intervention group
Group type: EXPERIMENTAL
Intervention: RV1 at 10 and 14 weeks
Number of subjects: 630
Study 22864647 — intervention group
Group type: EXPERIMENTAL
Intervention: CART model using variables from Norwood hospitalization
Number of subjects: 313
Study 22864647 — intervention group
Group type: EXPERIMENTAL
Intervention: CART model applied to ISV trial subjects
Number of subjects: 313
Study 22864647 — intervention group
Group type: EXPERIMENTAL
Intervention: PDI score lower than 70
Number of subjects: 313
Study 22864647 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk factors for PDI lower than 70
Number of subjects: 313
Study 20720188 — intervention group
Group type: EXPERIMENTAL
Intervention: tissue plasminogen activator (tPA)
Number of subjects: 60
Study 20720188 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 60
Study 18950439 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% lidocaine (active) injections
Number of subjects: 15
Study 18950439 — intervention group
Group type: COMPARATOR
Intervention: saline (control) injections
Number of subjects: 15
Study 15983790 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextroamphetamine (D-amph)
Number of subjects: 0
Study 12598775 — intervention group
Group type: EXPERIMENTAL
Intervention: Nevirapine 200 mg once weekly (cohort A, n = 12)
Number of subjects: 33
Study 12598775 — intervention group
Group type: EXPERIMENTAL
Intervention: Nevirapine 200 mg twice weekly (cohort B, n = 12)
Number of subjects: 33
Study 12598775 — intervention group
Group type: EXPERIMENTAL
Intervention: Nevirapine 200 mg every other day (cohort C, n = 9)
Number of subjects: 33
Study 10566923 — intervention group
Group type: EXPERIMENTAL
Intervention: Halothane anesthesia
Number of subjects: 12
Study 10566923 — intervention group
Group type: COMPARATOR
Intervention: Balanced anesthesia
Number of subjects: 12
Study 8604065 — intervention group
Group type: EXPERIMENTAL
Intervention: Lingual split technique
Number of subjects: 20
Study 8604065 — intervention group
Group type: COMPARATOR
Intervention: Conventional buccal approach
Number of subjects: 20
Study 8604065 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 20
Study 1782718 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac 50 mg preoperatively and 50 mg post-operatively
Number of subjects: 99
Study 1782718 — intervention group
Group type: COMPARATOR
Intervention: Diclofenac 100 mg post-operatively only
Number of subjects: 99
Study 6451354 — intervention group
Group type: EXPERIMENTAL
Intervention: Urea ointment
Number of subjects: 0
Study 6451354 — intervention group
Group type: COMPARATOR
Intervention: Placebo ointment (urea vehicle)
Number of subjects: 0
Study 31751935 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketone salt (KS) supplement (0.38 g/kg body mass)
Number of subjects: 16
Study 31751935 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 30786806 — intervention group
Group type: EXPERIMENTAL
Intervention: CBCT-guided TAT
Number of subjects: 88
Study 30786806 — intervention group
Group type: COMPARATOR
Intervention: Conventional TAT
Number of subjects: 88
Study 28231274 — intervention group
Group type: EXPERIMENTAL
Intervention: Early skin-to-skin contact (SSC)
Number of subjects: 35
Study 28231274 — intervention group
Group type: COMPARATOR
Intervention: Late skin-to-skin contact (SSC)
Number of subjects: 35
Study 25163489 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone 12 mg intramuscularly, two doses 24 hours apart
Number of subjects: 100
Study 25163489 — intervention group
Group type: COMPARATOR
Intervention: Usual care without steroids
Number of subjects: 100
Study 24008568 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 µg/kg remifentanil
Number of subjects: 30
Study 24008568 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 µg/kg remifentanil
Number of subjects: 30
Study 21390920 — intervention group
Group type: EXPERIMENTAL
Intervention: Verbal training condition
Number of subjects: 47
Study 21390920 — intervention group
Group type: EXPERIMENTAL
Intervention: Spatial training condition
Number of subjects: 47
Study 19155905 — intervention group
Group type: EXPERIMENTAL
Intervention: Dipslide culture technique
Number of subjects: 3048
Study 19155905 — intervention group
Group type: EXPERIMENTAL
Intervention: Leukocyte esterase and nitrite dipsticks
Number of subjects: 3048
Study 16881118 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept
Number of subjects: 20
Study 16881118 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 15359017 — intervention group
Group type: EXPERIMENTAL
Intervention: Mortality salience
Number of subjects: 0
Study 15359017 — intervention group
Group type: EXPERIMENTAL
Intervention: Subliminal exposure to 9/11-related stimuli
Number of subjects: 0
Study 15359017 — intervention group
Group type: EXPERIMENTAL
Intervention: Reminders of mortality and 9/11
Number of subjects: 0
Study 11526556 — intervention group
Group type: EXPERIMENTAL
Intervention: Discectomy
Number of subjects: 22
Study 11526556 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthroscopic lysis and lavage
Number of subjects: 22
Study 9416896 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibutilide
Number of subjects: 136
Study 9416896 — intervention group
Group type: EXPERIMENTAL
Intervention: Procainamide
Number of subjects: 136
Study 9416896 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 136
Study 7581113 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-alpha 2b
Number of subjects: 6
Study 7581113 — intervention group
Group type: EXPERIMENTAL
Intervention: Donor mononuclear cells with or without interleukin-2
Number of subjects: 6
Study 7581113 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytokine-mediated immunotherapy
Number of subjects: 6
Study 2198301 — intervention group
Group type: EXPERIMENTAL
Intervention: Buspirone 5-30 mg/day
Number of subjects: 40
Study 2198301 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 352099 — intervention group
Group type: EXPERIMENTAL
Intervention: Streptokinase
Number of subjects: 42
Study 352099 — intervention group
Group type: COMPARATOR
Intervention: Heparin
Number of subjects: 42
Study 31347384 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized video plus usual consent process
Number of subjects: 327
Study 31347384 — intervention group
Group type: COMPARATOR
Intervention: Usual consent process alone
Number of subjects: 327
Study 28284835 — intervention group
Group type: EXPERIMENTAL
Intervention: My Care My Call (MCMC) intervention
Number of subjects: 84
Study 28284835 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 84
Study 25545376 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferric maltol (30 mg twice a day)
Number of subjects: 128
Study 25545376 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 128
Study 25202177 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinesio Taping (KT) combined with conventional physical therapy (n=20)
Number of subjects: 40
Study 25202177 — intervention group
Group type: COMPARATOR
Intervention: Conventional physical therapy only (n=20)
Number of subjects: 40
Study 22442069 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute stress during encoding
Number of subjects: 44
Study 19445652 — intervention group
Group type: EXPERIMENTAL
Intervention: Tapentadol IR 50 mg
Number of subjects: 901
Study 19445652 — intervention group
Group type: EXPERIMENTAL
Intervention: Tapentadol IR 75 mg
Number of subjects: 901
Study 19445652 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxycodone HCl IR 10 mg
Number of subjects: 901
Study 19445652 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 901
Study 17242081 — intervention group
Group type: EXPERIMENTAL
Intervention: Fiberoptic Nasotracheal Intubation (FNI)
Number of subjects: 66
Study 17242081 — intervention group
Group type: COMPARATOR
Intervention: Fiberoptic Orotracheal Intubation (FOI)
Number of subjects: 66
Study 14981334 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 13
Study 11752036 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil (4000 mg)
Number of subjects: 24
Study 11752036 — intervention group
Group type: COMPARATOR
Intervention: Control oil (4000 mg)
Number of subjects: 24
Study 9056732 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional rice-lentil (khitchri) diet (KY)
Number of subjects: 0
Study 9056732 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional rice-lentil (khitchri) diet with soy formula (KY-Soy)
Number of subjects: 0
Study 9056732 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional rice-lentil (khitchri) diet with dilute buffalo milk (KY-B)
Number of subjects: 0
Study 9056732 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional diet and yogurt combination
Number of subjects: 0
Study 7686187 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.025% tretinoin cream applied once daily for 9 months
Number of subjects: 6
Study 7686187 — intervention group
Group type: COMPARATOR
Intervention: Vehicle cream applied once daily for 9 months
Number of subjects: 6
Study 3523043 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemo-immunotherapy (BCG or BCG plus tumor cell vaccine)
Number of subjects: 131
Study 3523043 — intervention group
Group type: COMPARATOR
Intervention: Adjuvant chemotherapy (CMF)
Number of subjects: 131
Study 30058744 — intervention group
Group type: EXPERIMENTAL
Intervention: nature sounds
Number of subjects: 200
Study 30058744 — intervention group
Group type: EXPERIMENTAL
Intervention: nature sounds and daylight
Number of subjects: 200
Study 30058744 — intervention group
Group type: EXPERIMENTAL
Intervention: nature sounds, daylight, and colour enhancements
Number of subjects: 200
Study 30058744 — intervention group
Group type: COMPARATOR
Intervention: control
Number of subjects: 200
Study 27272818 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion RSB analgesia
Number of subjects: 46
Study 27272818 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined active groups (single-dose, repeated-dose, continuous infusion)
Number of subjects: 46
Study 27272818 — intervention group
Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 46
Study 25342504 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin with nolatrexed (LP)
Number of subjects: 33
Study 25342504 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin with 5-fluorouracil (FP)
Number of subjects: 33
Study 22290239 — intervention group
Group type: EXPERIMENTAL
Intervention: Raltegravir
Number of subjects: 69
Study 22290239 — intervention group
Group type: COMPARATOR
Intervention: Control (no raltegravir)
Number of subjects: 69
Study 20482478 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 weeks of serial night casting
Number of subjects: 30
Study 20482478 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 weeks of weightbearing stretches
Number of subjects: 30
Study 20482478 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 30
Study 17610993 — intervention group
Group type: EXPERIMENTAL
Intervention: Imiquimod 5% cream applied thrice weekly for 8 weeks
Number of subjects: 90
Study 17610993 — intervention group
Group type: EXPERIMENTAL
Intervention: Imiquimod 5% cream applied thrice weekly for 12 weeks
Number of subjects: 90
Study 17610993 — intervention group
Group type: EXPERIMENTAL
Intervention: Imiquimod 5% cream applied thrice weekly for both durations
Number of subjects: 90
Study 17610993 — intervention group
Group type: EXPERIMENTAL
Intervention: Imiquimod 5% cream applied thrice weekly
Number of subjects: 90
Study 16083538 — intervention group
Group type: EXPERIMENTAL
Intervention: Mometasone furoate (MF) dry powder inhaler (DPI) 400 microg qd PM (one inhalation)
Number of subjects: 400
Study 16083538 — intervention group
Group type: EXPERIMENTAL
Intervention: Mometasone furoate (MF) dry powder inhaler (DPI) 400 microg qd PM (two inhalations)
Number of subjects: 400
Study 16083538 — intervention group
Group type: EXPERIMENTAL
Intervention: Mometasone furoate (MF) dry powder inhaler (DPI) 200 microg qd PM
Number of subjects: 400
Study 16083538 — intervention group
Group type: EXPERIMENTAL
Intervention: Mometasone furoate (MF) dry powder inhaler (DPI) 200 microg bid
Number of subjects: 400
Study 16083538 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 400
Study 11935106 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetic resonance discography using gadopentetate dimeglumine
Number of subjects: 13
Study 11935106 — intervention group
Group type: COMPARATOR
Intervention: Computed tomographic discography using intradiscal iodinated contrast agent
Number of subjects: 13
Study 10444726 — intervention group
Group type: EXPERIMENTAL
Intervention: Attendance at organized breast cancer screening program
Number of subjects: 1680
Study 10444726 — intervention group
Group type: COMPARATOR
Intervention: Expectation of pain at mammography
Number of subjects: 1680
Study 10444726 — intervention group
Group type: COMPARATOR
Intervention: Low confidence in breast cancer prevention capabilities
Number of subjects: 1680
Study 10444726 — intervention group
Group type: COMPARATOR
Intervention: Overoptimism about the sensitivity of mammography
Number of subjects: 1680
Study 10444726 — intervention group
Group type: COMPARATOR
Intervention: Perception of breast cancer risk as moderate
Number of subjects: 1680
Study 8544973 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam 5 mg
Number of subjects: 8
Study 8544973 — intervention group
Group type: EXPERIMENTAL
Intervention: Buspirone 5 mg
Number of subjects: 8
Study 8544973 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 1921538 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost-sharing
Number of subjects: 0
Study 7311224 — intervention group
Group type: EXPERIMENTAL
Intervention: Autotransfusion (AT)
Number of subjects: 144
Study 7311224 — intervention group
Group type: COMPARATOR
Intervention: Bank blood transfusion (control)
Number of subjects: 144
Study 31822114 — intervention group
Group type: EXPERIMENTAL
Intervention: Olive-pomace oil
Number of subjects: 0
Study 31822114 — intervention group
Group type: COMPARATOR
Intervention: Crude pomace-oil
Number of subjects: 0
Study 30795852 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone 30 mg/day
Number of subjects: 36
Study 30795852 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 27667534 — intervention group
Group type: EXPERIMENTAL
Intervention: KneeAlign (portable navigation device)
Number of subjects: 190
Study 27667534 — intervention group
Group type: COMPARATOR
Intervention: Conventional guides
Number of subjects: 190
Study 27233633 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored implementation intervention
Number of subjects: 28
Study 27233633 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 28
Study 25528574 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythropoietin 40,000 IU administered weekly for up to three doses
Number of subjects: 606
Study 25528574 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered weekly for up to three doses
Number of subjects: 606
Study 25528574 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythropoietin
Number of subjects: 606
Study 25528574 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 606
Study 22670572 — intervention group
Group type: EXPERIMENTAL
Intervention: Compassionate imagery
Number of subjects: 24
Study 22670572 — intervention group
Group type: COMPARATOR
Intervention: Relaxation (Control)
Number of subjects: 24
Study 19884557 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel
Number of subjects: 1010
Study 19884557 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab with docetaxel or vinorelbine
Number of subjects: 1010
Study 19884557 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel, trastuzumab, and FEC
Number of subjects: 1010
Study 19884557 — intervention group
Group type: EXPERIMENTAL
Intervention: Vinorelbine, trastuzumab, and FEC
Number of subjects: 1010
Study 19884557 — intervention group
Group type: COMPARATOR
Intervention: Trastuzumab
Number of subjects: 1010
Study 17535142 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiotherapy intervention from Monday to Saturday
Number of subjects: 262
Study 17535142 — intervention group
Group type: COMPARATOR
Intervention: Physiotherapy intervention from Monday to Friday
Number of subjects: 262
Study 15171968 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led follow-up on demand (NG)
Number of subjects: 264
Study 15171968 — intervention group
Group type: COMPARATOR
Intervention: Physician follow-up (PG)
Number of subjects: 264
Study 11797323 — intervention group
Group type: EXPERIMENTAL
Intervention: Conductive keratoplasty (CK)
Number of subjects: 233
Study 9548624 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha-tocopherol (50 mg daily)
Number of subjects: 2132
Study 9548624 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-carotene (20 mg daily)
Number of subjects: 2132
Study 9548624 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2132
Study 7991935 — intervention group
Group type: EXPERIMENTAL
Intervention: Addition of 30 cm of dead space (VD)
Number of subjects: 15